Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome

Summary

The primary aim is to test the reduction of bone marrow edema syndrome after a singular intravenous treatment with Zoledronic Acid within 6 weeks compared to placebo. The volume of the edema is defined as biometric data measured by the use of MRT before and six weeks after treatment. The hypothesis has to be checked whether Zoledronic Acid is efficient in the treatment of painful bone marrow edema. A statistically significant reduction of the edema in the MRT is considered as evidence for efficacy.

Timeline

Start

2011-05

Primary completion

2015-08-26

Completion

2015-08-26

Drugs

Indications